We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other ...
NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (BHVN) (NYSE: BHVN) and Merus N.V. (MRUS) (Nasdaq:MRUS), today announced a research ...
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - ...
Merus N.V. (NASDAQ:MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab ...
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...
We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are going to take a look at where Merus NV (NASDAQ:MRUS) stands against the other ...
Hosted on MSN
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled
Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.
Merus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago. These figures are ...
On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...
NEW YORK, Sept. 30, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results